Physician profile

Edward Chau

Cardiovascular Disease · La Jolla, CA

NPI 1821529587

$8,598.90

in general payments reported to CMS, 2019-2025

28 companies · $2,303 in 2025

The $2,303 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,347.45
Travel and Lodging$1,175.76
Grant$195.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $1,737.97 2023-2025 Mitraclip, Triclip, Dragonfly Opstar
Biotronik INC. $1,635.25 2021-2024 Acticor 7 Vr-T Dx, Edora 8 Dr-T, Nhancer Rx
Shockwave Medical, INC $1,479.32 2021-2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Philips North America LLC $694.04 2023-2025 Intracardiac Undivided, Igt Devices Undivided, (Ck4) Mcot
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $619.39 2021-2024 Lifevest
Boston Scientific Corporation $512.29 2024-2025 Watchman Flx, Watchman, General - Structural Heart
Edwards Lifesciences Corporation $238.24 2025 Sapien 3 Ultra Resilia
Amgen INC. $237.49 2022-2023 Repatha
Kestra Medical Technology Services, INC. $182.10 2025 Assure Wcd
Madrigal Pharmaceuticals $150.00 2025 Rezdiffra
Asahi Intecc USA, INC. $146.16 2025 Asahi Coronary Wires
Janssen Pharmaceuticals, INC $136.76 2021-2024 Xarelto
Kiniksa Pharmaceuticals, LTD. $122.31 2023 Arcalyst
Medtronic, INC. $114.09 2025 Linq II
Novartis Pharmaceuticals Corporation $107.88 2020-2025
Show all 28 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $107.80 2022-2024 Camzyos
Abiomed $47.81 2023 Impella
Pfizer INC. $45.60 2019-2020
Lantheus Medical Imaging, INC. $41.31 2024
Kiniksa Pharmaceuticals International, Plc $40.15 2024 Arcalyst
Astrazeneca Pharmaceuticals LP $39.21 2024-2025 Wainua, Farxiga
Heartflow, INC. $31.02 2022
Novo Nordisk INC $29.14 2024 Rybelsus, Ozempic
Cvrx, INC. $25.52 2025 Barostim Neo System
Boehringer Ingelheim Pharmaceuticals, INC. $24.50 2025 Jardiance
Regeneron Healthcare Solutions, INC. $21.13 2025 Evkeeza
Bayer Healthcare Pharmaceuticals INC. $17.23 2025
Cathworks, INC. $15.19 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Edward Chau

$8,598.90

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $2,303 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/8790227/edward-chau

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.